Cronex크로넥스

Quick answers about Cronex

What does Cronex do?

The company develops xenotransplantation technology, using genetically edited pigs as a source of organs and tissues that could be transplanted into humans to address shortages of donor organs. It also breeds and supplies Jeju minipigs, a Korean native breed used for drug testing, non-clinical research, medical training and biomedical development, and runs a contract research organization (CRO) business providing preclinical and other R&D services to pharmaceutical and biotech customers. Its breeding and research facilities are located in Cheongju and Jeju.

What is the market cap of Cronex?

The market capitalisation of Cronex was ₩4.6B at the close on Oct 27, 2026.

Who are the largest shareholders of Cronex?

According to the latest official filings, the largest reported holders are CNBICT (11.66%, as of Jul 31, 2026); Hwang Soon-hye (9.39%, as of Nov 20, 2025); Jang Jae-hyuk (5.17%, as of Jul 23, 2026).

When is the next earnings report from Cronex?

Korean companies rarely announce results dates in advance. Based on when Cronex filed the same report in past years, its next annual results is expected between Mar 20, 2027 and Mar 21, 2027.